แนวทางการดูแลผู้ป่วยมะเร็งปอดในปี 2553
Article Sidebar
Main Article Content
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
Goldstraw P, Crowley JJ. The International Association for the Study of Lung Cancer International staging project on lung cancer. J Thorac Oncol 2006; 1: 281-6.
Rami-Porta R, Ball D, Crowley J, Giroux DJ, Travis WD, Tsuboi M, et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 593-602.
Rusch VW, Crowley J, Giroux DJ, Goldstraw P, Im JG, T suboi M, et al. The IASLC lung cancer project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 603-12.
Postmus PE, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz EF Jr, et al. The IASLC lung cancer project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007; 2: 686-93.
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol 2007; 2: 706-14.
Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the cancer and leukemia group B, Radiation therapy oncology group, and the north central cancer treatment group study groups. J Clin Oncol 2008; 26: 5014-7.
Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephen RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by LACE collaborative Group. J Clin Oncol 2008; 26: 3352-9.
Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer. J Thorac Oncol 2007; 2: 1067-77.
Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-53.
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-44.
Kim ES, Hirsch V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008; 372: 1809-18.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123-32.
Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, et al. First-line gefitinib in patients with advanced non-small cell lung cancer harbouring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-9.
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma. New Engl J Med 2009; 361:1018-20.
Scagliotti GV, Parik P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
Souquet PJ, Chauvin F, Boissel JP, Cellerino P, Cormier Y, Ganz PA, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21.
Anonymous. Chemotherapy in non-small cell lung cancer: A meta-analysis using update data on individual patients from 52 randomized trials. Non-Small Cell Lung Cancer Collaborative Group. Br Med J 1995; 311: 899-909.
Ciuleanu TE, Brodowicz T, Belani CP. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. J Clin Oncol 2008; 26: 8011. [Abstract]
Cappuzzo F, Ciuleanu T, Stelmakh L. A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non-progression with 1st-line platinum-based chemotherapy in patients with advanced NSCLC: SATURN study. Proc Am Soc Clin Oncol 2009. [Abstract]